I. CALL TO ORDER
The meeting of the Benefits Committee was called to order at 9:02 a.m. by Trustee Linda Currivan Musto, Chairperson, in the EUTF Board Room, City Financial Tower, 201 Merchant Street, Suite 1700, Honolulu, Hawaii, on Monday, December 16, 2019.

Trustees Damien Elefante and Laurel Johnston entered the meeting at 9:03 a.m. and 9:04 a.m., respectively.

Chairperson Currivan Musto informed the Committee and public of the recent passing of longtime EUTF advisor, Mr. Thomas Morrison, Segal Consulting, and the significant contributions to the EUTF that he made over the years. The Committee paused for a moment of silence to remember Mr. Morrison. She also introduced Mr. Morrison’s replacement, Mr. Steve Murphy. Mr. Murphy provided his background and credentials.

II. MINUTES – November 18, 2019
The Benefits Committee reviewed the draft minutes of November 18, 2019.
MOTION was made and seconded to approve the minutes of November 18, 2019 as circulated. (Elefante/Johnston) The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-3)

III. EXECUTIVE SESSION
MOTION was made and seconded to move into Executive Session at 9:06 a.m. (Johnston/Elefante) The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-3)

The regular meeting reconvened from Executive Session at 9:46 a.m.

Chairperson Currivan Musto reported that the Committee in Executive Session approved the Executive Session minutes of November 18, 2019 as circulated.

IV. NEW BUSINESS
A. HMSA and Kaiser Coverage of Genetic Therapies
   Mr. Derek Mizuno summarized the memoranda from HMSA and Kaiser in response to Segal Consulting’s memorandum at the November 19, 2019 Board meeting regarding coverage of genetic therapies noting that coverage is provided, there are no facilities providing such services in Hawaii and there have been no such claims to date.

B. CVS Advanced Control Specialty Formulary
   Mr. Mizuno informed the Board that this item was placed on the agenda because of the recent issue with non-grandfathering of an excluded transplant medication when a change was made to the preferred specialty drug under the CVS Advanced Control Specialty Formulary (ACSF). Ms. Sandra Benevides, Mr. Kurt Neuenfeld, and Dr. Arnett discussed the purpose, history, methods, specialty classes impacted, clinically based decision making, and cost savings of ACSF.

C. CVS Biosimilars and Generics
   Ms. Benevides, Mr. Neuenfeld and Dr. Arnett provided education on generic equivalents and alternatives, biologics and biosimilars including manufacturing countries, safety guidelines and recall rates (generics). Dr. Arnett informed the Committee that CVS is considering sample testing of prescription drugs dispensed by CVS pharmacies and mail order. Chairperson Currivan Musto requested that CVS keep them informed about their sample testing.

D. CVS EUTF High Cost Multivitamins with Folic Acid Plan Options
   Ms. Benevides, Mr. Neuenfeld and Dr. Arnett presented possible options to exclude multivitamins with folic acid (1 mg or more) or all multivitamins except prenatal and pediatric noting the high cost as compared to obtaining prescription folic acid and a multivitamin separately or prescription folic acid and an over-the-counter multivitamin. This item was identified in the quarterly reports as a driver in prescription drug plan costs.
MOTION was made by the Committee to recommend to the Board exclusion of all multivitamins except prenatal and pediatric vitamins from the EUTF active employee, non-Medicare retiree and EGWP retiree wrap plans, excluding HSTA VB plans, effective April 1, 2020. (Johnston/Elefante) Trustee Christian Fern questioned whether CVS should be educating the prescribers about lower cost alternatives. Mr. Mizuno responded that EUTF staff, Segal and CVS will look into outreach to the prescribers. The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-3)

V. NEXT MEETING DATE
The next Benefits Committee meeting is tentatively scheduled for March 23, 2020, the day before the March Board meeting.

VI. ADJOURNMENT
MOTION was made and seconded for the Board to adjourn meeting at 11:00 a.m. (Hidano/Uwaine) The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-3)

Respectfully submitted,

/s/

Linda Currivan Musto, Chairperson

APPROVED ON April 27, 2020

DOCUMENTS DISTRIBUTED:
1. Draft Benefits Committee Minutes of November 18, 2019. (2 pages)
5. RxInsights, Redacted EUTF Non-Medicare Retirees, Jan 2019-Sep 2019, Quarterly Prescription Benefits Review. (13 pages)
10. Redacted Version, Biosimilars and Generics by CVS Health dated 12/16/19. (20 pages)
11. EUTF High-Cost Multivitamins with Folic Acid Plan Options-Redacted Version by CVS Health dated 12/16/19. (8 pages)